Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-30

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary hypertension. We hypothesize that changes in the mitochondrial function of blood cells and oxidative stress may be early markers of disease progression and severity.

The study will also explore how these blood markers relate to routine clinical and heart function measurements, such as echocardiography, right heart catheterization, 6-minute walk tests, and functional status, to see if they can help monitor patients over time and guide personalized care.

This is a non-interventional study. Blood samples will be collected during routine visits planned for diagnosis and follow-up. The study will include 120 patients diagnosed with pre-capillary pulmonary hypertension, who will be followed for 3 years. Blood samples will be taken up to three times per year to measure mainly oxidative stress and mitochondrial function in blood cells. These measurements will be compared with clinical tests to see if they can help predict the course of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical, Radiological, Tissue and Biological Phenotyping for the Analysis of the Transition From Physiology to Pathology in Pulmonary Diseases With Pulmonary Hypertension

NCT07184671

Pulmonary Hypertension Chronic Pulmonary Disease

NOT_YET_RECRUITING

Exploratory Metabolomics Study of Exhaled Breath in Pulmonary Embolism

NCT04001179

Pulmonary Embolism

TERMINATED

Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT02035293

Chronic Obstructive Pulmonary Disease Patients Hospitalized for a COPD Exacerbation

COMPLETED NA

Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans

NCT00621075

Pulmonary Arterial Hypertension

COMPLETED

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072

Secondary Pulmonary Arterial Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-capillary Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients with pre-Capillary pulmonary hypertension

Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (≥18 years) diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization
* Patients classified according to the international clinical classification:

* Group 1: Pulmonary arterial hypertension (PAH)
* Group 3: Pulmonary hypertension associated with chronic respiratory diseases and/or hypoxia
* Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)
* Patients scheduled for routine clinical follow-up and/or right heart catheterization at the study center.
* Ability and willingness to provide informed consent for participation and data analysis.

Exclusion Criteria

* Postcapillary pulmonary hypertension (pulmonary arterial wedge pressure \>15 mmHg).
* Conditions precluding safe blood sampling (e.g., severe anemia, coagulopathy).
* Patients already enrolled in interventional clinical trials that could interfere with mitochondrial or oxidative stress measurements
* Patients unable or unwilling to provide informed consent
* Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No